At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 138 enrolled
Drug / intervention
Elucirem +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Performance of Elucirem (Gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) Perfusion of Brain Gliomas Phase IIIb Clinical Trial
In Brief
A Phase 3 clinical trial evaluating Elucirem and Dotarem for Brain Tumor, Primary and Brain Tumor, Recurrent. Completed, enrolled 138 participants across 11 sites in 3 countries.
Detailed Summary
This trial aimed to study the performance of Elucirem (gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) perfusion of brain gliomas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Tumor, Primary, Brain Tumor, Recurrent
CountriesHungary, Italy, Poland
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
Enrollment StartSep 2023
First PostedSep 2023
Primary CompletionNov 2024
TodayJul 2026
First PostedSep 28, 2023
Enrollment StartSep 7, 2023
Primary CompletionNov 28, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 2.8 years ago
Interventions
Eluciremdrug
Intravenous administration
Dotaremdrug
Intravenous administration